Lilium (LILMF) 6-K 28 Sep 22 2022 Q2 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2022
Document Information [Line Items]
Document Type	6-K
Entity Registrant Name	Lilium N.V.
Document Period End Date	Jun. 30, 2022
Entity Central Index Key	0001855756
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

Interim Condensed Consolidated

Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)
Revenue		€ 47
Cost of sales		(11)
Gross profit		36
Research and development expenses	€ (83,028)	(58,762)
General and administrative expenses	(46,987)	(38,718)
Selling expenses	(9,574)	(6,376)
Other income	2,599	153
Other expenses	(1,393)	(126)
Operating loss	(138,383)	(103,793)
Finance income	16,597	6,810
Finance expenses	(931)	(13,094)
Financial result	15,666	(6,284)
Share of loss in a joint venture/ associate	(1,457)	(201)
Loss before income tax	(124,174)	(110,278)
Income tax income / (expense)	478	(199)
Net loss for the period	(123,696)	(110,477)
Other comprehensive income / (loss)
Other comprehensive income that may be reclassified to profit or loss	(5)	22
Exchange differences on translation of foreign business units	(5)	22
Items that will not be subsequently reclassified to profit or loss	(68)	(22)
Remeasurement of defined pension benefit obligation	(68)	(22)
Other comprehensive income / (loss)	(73)
Total consolidated comprehensive loss for the period	€ (123,769)	€ (110,477)
Loss per share basic	€ (0.43)	€ (0.53)
Loss per share diluted	€ (0.43)	€ (0.53)

Interim Condensed Consolidate_2

Interim Condensed Consolidated Statement of Financial Position - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets
Intangible assets	€ 977	€ 1,394
Property, plant and equipment	32,060	30,610
Investment in a joint venture / associate	13,597	15,054
Other financial assets	3,189	3,779
Non-financial assets	6,251	8,113
Non-current assets	56,074	58,950
Other financial assets	122,420	219,625
Non-financial assets	31,948	22,994
Cash and cash equivalents	103,132	129,856
Current assets	257,500	372,475
Total Assets	313,574	431,425
Shareholders' Equity and Liabilities
Subscribed capital	41,177	40,138
Share premium	779,347	779,141
Other capital reserves	252,940	240,430
Treasury shares	(151)	(151)
Accumulated loss	(840,830)	(717,134)
Accumulated other comprehensive income / (loss)	14	87
Shareholders' equity	232,497	342,511
Other financial liabilities	23
Lease liabilities	9,399	9,861
Provisions	450	373
Trade and other payables	5,032	2,906
Deferred tax liabilities	10	10
Non-current liabilities	14,914	13,150
Other financial liabilities	36
Lease liabilities	2,939	1,962
Share-based payments liabilities	6,801	8,028
Provisions	3,756	2,422
Income tax payable	35	552
Warrants	5,218	21,405
Trade and other payables	36,524	35,335
Other non-financial liabilities	10,854	6,060
Current liabilities	66,163	75,764
Total Shareholders' Equity and Liabilities	€ 313,574	€ 431,425

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statement of Changes in Shareholders' Equity - EUR (€) € in Thousands	Subscribed capital	Share premium	Other capital reserves	Treasury shares	Accumulated loss	Currency translation reserve	Remeasurement of defined pension benefit obligation	Total
Retrospective application of stock split	€ 29,481	€ (29,456)		€ (25)
January 1, 2021, as adjusted	29,550	224,359	€ 110,055	(25)	€ (306,098)	€ 39	€ (158)	€ 57,722
Beginning balance at Dec. 31, 2020	69	253,815	110,055	0	(306,098)	39	(158)	57,722
Net loss for the period					(110,477)			(110,477)
Other comprehensive income and expenses						22	(22)
Total comprehensive income (loss)					(110,477)	22	(22)	(110,477)
Share-based payments			17,925					17,925
Convertible loans	2,464	127,814	(34,084)					96,194
Ending balance at Jun. 30, 2021	32,014	352,173	93,896	(25)	(416,575)	59	(178)	61,364
Beginning balance at Dec. 31, 2021	40,138	779,141	240,430	(151)	(717,134)	83	4	342,511
Net loss for the period					(123,696)			(123,696)
Other comprehensive income and expenses						(5)	(68)	(73)
Total comprehensive income (loss)					(123,696)	(5)	(68)	(123,769)
Share-based payments			12,836					12,836
Conversion share-based pay-ments into shares	1,007	206	(990)					223
ELOC commitment shares	32		664					696
Ending balance at Jun. 30, 2022	€ 41,177	€ 779,347	€ 252,940	€ (151)	€ (840,830)	€ 78	€ (64)	€ 232,497

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statement of Cash Flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flow from operating activities
Net loss for the period	€ (123,696)	€ (110,477)
Adjustments to reconcile consolidated net profit (loss) to net cash flows
Income tax (income)/expense	(478)	199
Net interest	654	3,649
Depreciation and amortization	3,743	2,980
Expenses for share-based payments	12,272	17,925
Net (gains)/losses from the disposal of intangibles and PP&E	0	(8)
Share of loss in a joint venture/ associate	1,457	201
Fair value changes of financial instruments and expected credit losses (ECL)	(16,320)	2,634
Income taxes refunded/(paid)	(39)	(18)
Expense from change in provisions	1,475	92
Working capital adjustments:
Changes in trade and other payables	1,028	8,933
Changes in other assets and liabilities	(2,817)	(1,022)
Cash flow from operating activities	(122,721)	(74,912)
Cash flow from investing activities
Purchases of intangible assets	(103)	(1,037)
Purchases of and advance payments on property, plant and equipment	(2,169)	(4,658)
Disposals of intangible assets, property, plant and equipment	9	8
Proceeds from short-term investments	179,823	50,000
Payments for short-term investments	(80,000)
Payments for promissory notes		(1,051)
Payments for the acquisition of an associate		(8,502)
Interest paid	(121)
Interest received		7
Cash flow from investing activities	97,439	34,767
Cash flow from financing activities
Proceeds from convertible loans		1,850
Proceeds from share capital increase and capital contribution	255	7
Principal elements of lease payments	(1,315)	(1,040)
Interest paid	(417)	(65)
Cash flow from financing activities	(1,477)	752
Cash-based changes in cash and cash equivalents	(26,759)	(39,393)
Effect of foreign exchange rate changes and ECL on cash and cash equivalents	35	(15)
Net (decrease) / increase in cash and cash equivalents	(26,724)	(39,408)
Cash and cash equivalents at the beginning of the period	129,856	102,144
Cash and cash equivalents at the end of the period	€ 103,132	€ 62,736

Corporate Information

Corporate Information	6 Months Ended
	Jun. 30, 2022
Corporate Information
Corporate Information	1. Lilium N.V., together with its German subsidiary Lilium GmbH (“Lilium” or the “Group”), is a start-up in the field of urban air mobility and intends to make regional air mobility a reality. Since its founding, Lilium GmbH has primarily engaged in research and development of a self-developed electric Vertical Takeoff and Landing (eVTOL) jet (the “Lilium Jet”) for production and operation of a regional air mobility service as well as related services. Lilium N.V. is a public company under Dutch law and is registered under the Dutch trade register number 82165874. Lilium N.V. has its activities exclusively in Germany. The registered headquarters is Claude-Dornier-Str. 1, Geb. 335, 82234 Wessling, Germany. Lilium GmbH is a German limited-liability company and is registered in the commercial register at the Bavaria District Court Munich Germany under the number 216921. Prior to September 14, 2021, Lilium N.V. was a shell company with no active trade or business, and all relevant assets and liabilities, as well as income and expenses, were borne by Lilium GmbH. Therefore, the interim condensed consolidated financial statements for the six-months period ended on June 30, 2021 represent consolidated financial statements of Lilium GmbH. The share split of 1 : 2,857 that was effectuated just prior to the capital reorganization has been retrospectively applied to prior periods’ shareholders’ equity. The interim condensed consolidated financial statements of Lilium N.V. and its subsidiaries, collectively referred to as “the Company”, “the Group” or the “Lilium Group”, for the six months period ended June 30, 2022, were authorized for issue by the Management Board on September 28, 2022. Consolidated entities are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ equity interest ​ ​ ​ ​ ​ ​ owned in % ​ ​ ​ Country of ​ Date of ​ June 30, ​ June 30, Name ​ Incorporation ​ incorporation ​ 2022 ​ 2021 ​ Lilium N.V. Netherlands ​ March 11, 2021 100.0 % n/a ​ Lilium GmbH Germany ​ February 11, 2015 100.0 % 100.0 % Lilium Schweiz GmbH Switzerland ​ December 8, 2017 100.0 % 100.0 % Lilium Aviation UK Ltd. United Kingdom ​ December 20, 2017 100.0 % 100.0 % Lilium Aviation Inc. United States ​ July 1, 2020 100.0 % 100.0 % Lilium eAircraft GmbH Germany ​ August 17, 2020 100.0 % 100.0 % Stichting JSOP Netherlands ​ September 10, 2021 0.0 % n/a ​ Lilium Aviation Spain SL Spain ​ April 7, 2022*) 100.0 % n/a ​ *) date of purchase of a shell company (company without active business).

Basis of Preparation and Change

Basis of Preparation and Changes to the Groups Accounting Policies	6 Months Ended
	Jun. 30, 2022
Basis of Preparation and Changes to the Group's Accounting Policies
Basis of Preparation and Changes to the Group's Accounting Policies	2. Basis of Preparation and Changes to the Group’s Accounting Policies The Group’s interim condensed consolidated financial statements for the six-months periods ended June 30, 2022 and 2021 are prepared in accordance with IAS 34 Interim Financial Reporting. The interim condensed consolidated financial statements have been prepared on a going concern basis, applying a historical cost convention, unless otherwise indicated. They are prepared and reported in thousands of Euro (“€ thousand”) except where otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2021. New standards, interpretations and amendments adopted by the Group The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2021, except for the adoption of new standards effective as of January 1, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several amendments apply for the first time in 2022, but do not have an impact on the interim condensed consolidated financial statements of the Group.

Significant Accounting Judgment

Significant Accounting Judgments, Estimates and Assumptions	6 Months Ended
	Jun. 30, 2022
Significant Accounting Judgments, Estimates and Assumptions
Significant Accounting Judgments, Estimates and Assumptions	3. The preparation of the Group’s interim condensed consolidated financial statements requires the management to make judgements, estimates and assumptions that affect the reported amounts in the interim condensed consolidated financial statements. In preparing these interim condensed consolidated financial statements, management exercises its best judgement based upon its experience and the circumstances prevailing at that time. The estimates and assumptions are based on available information and conditions at the end of the financial period presented and are reviewed on an ongoing basis. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods. The significant judgements made by management in applying the Group’s accounting policies and key sources of estimation uncertainty were the same as those described in the last annual financial statements. Significant judgments were made in determining the forfeiture in relation to a key management persons performance stock options. Please refer to note 17 for more details. The Group operates its business as a single operating segment, which is also its reporting segment. An operating segment is defined as a component of an entity for which discrete financial information is available and whose results of operations are regularly reviewed by the chief operating decision maker. The Group’s chief operating decision maker is the Chief Executive Officer, who reviews results of operations to make decisions about allocating resources and assessing performance based on consolidated financial information.

COVID 19 Risks and Uncertaintie

COVID 19 Risks and Uncertainties	6 Months Ended
	Jun. 30, 2022
COVID 19 Risks and Uncertainties
COVID 19 Risks and Uncertainties	4. Since January 2020, the Corona Virus (COVID-19) has spread worldwide. The strict measures to stop the spread of COVID-19 adopted in several countries where the Group operates had resulted in the majority of the Company’s workforce working from home with a small number of teams with special purposes for development of the Lilium Jet remaining onsite. Since April 2022, a larger number of the workforce has returned to the offices. Modern forms of communication enabled contact to be maintained between various members of staff and deadlines defined before the period during which employees were working from home have been complied with. We continue to take actions as may be required or recommended by government authorities or in the best interests of our employees and business partners but COVID-19 could also affect the operations of our suppliers and business partners which may result in delays or disruptions in the supply chain of our components and delay the development and rollout of a vertiport network and commercial operations. The potential delay did not trigger an impairment of assets. Additional costs were incurred related to health, safety and transportation of employees which remained onsite, however, the impact of these did not materially impact these consolidated financial statements. The current uncertainty regarding the consequences and duration of COVID-19 has negatively impacted the ability to develop a precise forecast for product development. Based on COVID-19 developments throughout 2020 and 2021 and the latest developments in 2022, the Group is expecting that business operation can be continued, no other impacts have been considered relevant.

War in Ukraine

War in Ukraine	6 Months Ended
	Jun. 30, 2022
War in Ukraine
War in Ukraine	5. Near the end of February 2022, a war started between Ukraine and Russia, and the tensions between Russia and the Western world are rising. Bilateral sanctions between Russia and Western countries worsen the business conditions worldwide, especially for companies working in Russia or with Russian companies. Currently, we do not see any major direct impact on Lilium’s business; Lilium has no suppliers in Russia or Ukraine. Nonetheless, the general worldwide economic climate worsens as well and already leads to increasing prices for raw materials and other parts provided by suppliers.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2022
Going Concern
Going Concern	6. The financial statements have been prepared on a basis that assumes the Group will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Management assessed the Group’s ability to continue as a going concern and evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Group’s ability to continue as a going concern using all information available about the future, focusing on the twelve-month period after the issuance date of the financial statements. Historically, the Group has funded its operations primarily through capital raises and loans from shareholders. In 2021, management realized plans to finance these investments and costs with the US public listing via a Reorganization which was completed in September 2021 (see consolidated financial statements as of December 31, 2021). Since the inception the Group has incurred recurring losses and negative cash flows from operations including accumulated losses of €841 million. The Group expects to continue generating operating losses for several years. Based on the business plan the Group depends on additional financing for development activities and operations. This realization of the Reorganization had been crucial for the Group’s ability to continue as a going concern. Based on its recurring losses from operations since inception, expectation of continuing operating losses in the future and the need to raise additional capital to finance its future operations, the Group has concluded that there is substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Research and Development Expens

Research and Development Expenses	6 Months Ended
	Jun. 30, 2022
Research and Development Expenses.
Research and Development Expenses	7. For the six-months period ended June 30, 2022, research and development expenses consisted of €38,686 thousand in personnel expenses, including share-based payment expenses; €20,047 thousand expenses incurred by suppliers on behalf of the Group in preparation for certification and serial production of the Lilium Jet; €11,549 thousand in contractor and consulting expenses; €4,594 thousand in testing component and material costs; €2,837 thousand on amortization and depreciation expenses and €5,315 thousand on other miscellaneous expenses.

General and Administrative Expe

General and Administrative Expenses	6 Months Ended
	Jun. 30, 2022
General and Administrative Expenses.
General and Administrative Expenses	8. For the six-months period ended June 30, 2022, general and administrative expenses included €16,895 thousand personnel expenses, including share-based payment expenses; €14,921 thousand contractor and consulting expenses; €7,653 thousand IT costs, including a Cloud Subscription contract to a related party (see note 21); €3,358 thousand in insurance premiums primarily related to Directors and Officers’ Liability insurance; and €4,160 thousand other miscellaneous expenses.

Selling Expenses

Selling Expenses	6 Months Ended
	Jun. 30, 2022
Selling Expenses.
Selling Expenses	9. For the six-months period ended June 30, 2022, selling expenses consisted of €7,319 thousand personnel expenses, including share-based payment expenses, and €2,255 thousand miscellaneous other expenses.

Financial Result

Financial Result	6 Months Ended
	Jun. 30, 2022
Financial Result
Financial Result	10. Financial result is comprised of the following for the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ In € thousand 2022 2021 Finance income ​ 16,597 ​ 6,810 thereof: fair value changes 16,350 6,757 thereof: reversal of expected credit losses 124 — Finance expenses (931) (13,094) thereof: interest portion of lease payments (230) (214) thereof: fair value changes (67) (9,391) thereof: expected credit losses (87) — thereof: interest on convertible loans — (3,422) Financial result 15,666 (6,284) ​ Fair value changes in the current period result from the warrant revaluation (€16,187 thousand in financial income) and from a foreign currency exchange forward contract entered into in June 2022 (€163 thousand in financial income). Finance expenses of €67 thousand relate to a fair value loss on the money market funds. Fair value changes in the prior period result from the embedded derivatives of the convertible loans (2021: €6,757 thousand in finance income), as the respective convertible loan has been converted, as well as from a foreign currency exchange forward contract entered into in May 2021 (€9,376 thousand in finance expense).

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Taxes
Income Taxes	11. The Group calculated the period income tax expense, during the six-months periods ended June 30, 2022 and 2021, the Group recorded consolidated income tax income of (€478) thousand and expense of €199 thousand, respectively. These income taxes mainly relate to foreign subsidiaries. Major deferred income taxes have not been recorded. The netting of deferred tax liabilities and deferred tax assets results in a net deferred tax asset. The net deferred tax asset has been valuated with zero. Deferred tax assets on the tax losses carried forward are not recognized either given the tax losses carried forward relate to entities with a history of losses.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment
Property, Plant and Equipment	12. During the six-months period ended June 30, 2022, the Group acquired assets with a cost of €4,320 thousand (June 30, 2021: €5,700 thousand): ​ ​ ​ ​ ​ ​ In € thousand June 30, 2022 December 31, 2021 Right of use assets – buildings, net ​ 11,519 ​ 10,910 Technical machinery, net 10,083 9,069 Office and other equipment 4,178 4,380 Furniture and fixtures, net 3,672 3,555 Technical machinery under construction 1,014 884 Other, net 1,594 1,812 Property, Plant and Equipment, net 32,060 30,610 ​ Assets with a net book value of €9 thousand were disposed by the Group during the six-months period ended June 30, 2022 (June 30, 2021: €0 thousand), resulting in a net gain on disposal of €0 thousand (June 30, 2021: net gain of €8 thousand). No indicators of impairment existed which would have required items of property, plant and equipment to be tested for impairment in the six-months periods ended June 30, 2022 and 2021.

Investment in a Joint Venture _

Investment in a Joint Venture / Associate	6 Months Ended
	Jun. 30, 2022
Investment in a Joint Venture / Associate
Investment in a Joint Venture / Associate	13. Investment in Zenlabs The Group’s share in Zenlabs Energy, Inc is diluted in the period to 31.36 % through the issuance of 273,227 and 350,000 series B preferred stock by Zenlabs respectively to other investors, offset by a share buyback of 273,227 common stock. As of December 31, 2021, the Group accounted for the Zenlabs investment as an associate under IAS 28 ‘Investment in associates and joint ventures’ based on the Group’s significant influence on the business of Zenlabs. With the amended investors agreement dated May 12, 2022, management concluded that Lilium and two preferred stockholders have joint control of Zenlabs. The Group has concluded that as a result of the transaction Zenlabs is now classified as a joint venture under IAS 28. Accordingly, Lilium continues equity accounting without any change for the six-months period ended June 30, 2022. The gain on the dilution of an interest in an equity-accounted investee of €368 thousand is recognized in the share of loss in a joint venture. The following table illustrates the summarized valuation of the Group’s investment in Zenlabs: ​ ​ ​ ​ In € thousand Carrying Value January 1, 2022 ​ 15,054 Share of loss in a joint venture/ associate (1,457) June 30, 2022 13,597 ​

Other Financial Assets

Other Financial Assets	6 Months Ended
	Jun. 30, 2022
Other Financial Assets
Other Financial Assets	14. Lilium has placed part of its liquidity in fixed term deposits with a remaining term of more than 3 months to gain a better return on the surplus liquidity. As of June 30, 2022, the Group held €119,561 thousand (December 31, 2021: €119,664 thousand) in fixed-term deposits. During the period, €79,970 thousand cash was received from matured deposits including €121 thousand interest expense, and €80,000 thousand was invested into new fixed-term deposits. During the period, the Group sold all investments in Money Market Funds for total proceeds of €99,853 thousand (December 31, 2021: €99,919 thousand). In addition, Lilium entered into a foreign currency exchange contract to reduce foreign currency risk from US dollar exposure. As of June 30, 2022, the foreign currency exchange contract was recognized as a derivative financial asset with a fair value of €163 thousand.

Non-Financial Assets

Non-Financial Assets	6 Months Ended
	Jun. 30, 2022
Non-Financial Assets
Non-Financial Assets	15. Non-financial assets are as follows: ​ ​ ​ ​ ​ ​ In € thousand June 30, 2022 December 31, 2021 Advance payments ​ 6,251 ​ 8,113 Total non-current non-financial assets 6,251 8,113 Value added tax claims 22,611 12,602 Prepaid expenses 6,905 9,924 Miscellaneous other current non-financial assets 2,432 468 Total current non-financial assets 31,948 22,994 Total non-financial assets 38,199 31,107 ​ In the period to June 30, 2022, claims for value added taxes increased by €10,009 thousand largely due to claims in Germany.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2022
Shareholders' Equity
Equity	16. On September 14, 2021, upon the Reorganization, all outstanding Lilium GmbH shares (Common shares, Seed shares, Series A, Series B1 and Series B2) have been transferred to Class A shares in the relationship 1 : 2,857 outstanding The movements of the shares issued during the six-months period ended June 30, 2021, have been retrospectively adjusted to reflect the share split that occurred in 2021, prior to the Reorganization. Accordingly, this retrospective application of the share split has increased subscribed capital by €29,481 thousand, decreased share premium by €29,456 thousand and decreased treasury shares by €25 thousand as of January 1, 2021; retrospective application leaves total shareholders’ equity unchanged. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ Supervoting ​ ​ ​ Lilium ​ ​ shares ​ shares ​ ​ ​ GmbH (in units) (Class A) (Class B) Total Total 1 Outstanding as of January 1, 2021 69,031 — 69,031 69,031 Issued as of January 1, 2021 69,103 — 69,103 69,103 Retrospective application of share split 172,945,103 24,413,065 197,358,168 — Retrospective application of share split (treasury shares) (205,632) — (205,632) — Outstanding as of January 1, 2021, as adjusted 172,808,502 24,413,065 197,221,567 69,031 Issued as of January 1, 2021, as adjusted 173,014,206 24,413,065 197,427,271 69,103 Issued shares - convertible loans 20,533,259 — 20,533,259 7,187 Outstanding as of June 30, 2021, as adjusted 193,341,761 24,413,065 197,221,567 76,218 Issued as of June 30, 2021, as adjusted 193,547,465 24,413,065 197,427,271 76,290 ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of January 1, 2022 259,990,224 24,413,065 284,403,289 — Issued as of January 1, 2022 261,244,915 24,413,065 285,657,980 — Issued shares for share-based payments exercised 8,392,206 — 8,392,206 — Warrants exercised 10 — 10 — ELOC commitment shares 262,697 — 262,697 — Outstanding as of June 30, 2022 268,645,137 24,413,065 293,058,202 — Issued as of June 30, 2022 269,899,828 24,413,065 294,312,893 — 1 During the six-months period ended June 30, 2022, in total 8,392,206 shares have been issued due to the execution of vested share-based payments; EUR 1,007 thousand have been added to subscribed capital, thereof €990 thousand transfer from other capital reserves, and €206 thousand to share premium. As 10 warrants have been exercised, 10 shares have been issued. €1.20 have been paid into subscribed capital and €103.33 into the capital reserve. €5.45 have been transferred from share-based payment liabilities to other capital reserves. A number of 262,697 shares have been issued as compensation for the share purchase agreement (ELOC – see below); the amount of €32 thousand have been paid into subscribed capital, and the remaining fair value of the shares of €664 thousand have been expensed to other capital reserves. Share Purchase Agreement (“ELOC”) On June 3, 2022, the Group entered into a Share Purchase Agreement and a Registration Rights Agreement with Tumim Stone Capital LLC (“Tumim Stone”), pursuant to which (a) the Group agreed to issue 262,697 (the “Commitment Shares”) of the Group’s Class A shares to Tumim Stone and (b) Tumim Stone has committed to purchase, subject to certain limitations, up to $75 million of Class A shares. Under the terms and subject to the conditions of the Share Purchase Agreement, the Group has the right, but not the obligation, to sell to Tumim Stone, and Tumim Stone is obligated to purchase, Class A shares up to the total commitment of $75 million. Such sales of Class A shares by the Group, if any, will be subject to certain limitations, and may occur from time-to-time in the Group’s sole discretion, over the period commencing once certain conditions specified in the Share Purchase Agreement are satisfied, including the filing and securing effectiveness of the registration statement and ending on the first day of the month following the 24-month anniversary of the closing date. Class A shares up to the total commitment of $75 million will be issued from the Group to Tumim Stone at a discount to the volume-weighted average price on the date a purchase notice is deemed delivered from the Group to Tumim Stone. The Group shall not issue or sell any Class A shares to Tumim Stone under the Share Purchase Agreement that, when aggregated with all other Class A shares then beneficially owned by Tumim Stone and its affiliates, would result in Tumim Stone beneficially owning more than 4.99 % of the outstanding Class A shares (the “Beneficial Ownership Limitation”); provided that Tumim Stone may, in its sole discretion, elect to increase the Beneficial Ownership Limitation to permit Tumim Stone to beneficially own up to 9.99 % of the outstanding Class A shares. The Group determined that the right to issue Class A shares represents a freestanding purchased put option and the purchased put option was classified as a derivative asset with a fair value of zero at inception and as of June 30, 2022. Given that the Group believes that it is probable that it will utilize the facility in full, the fair value of the Commitment Shares issued under the Share Purchase Agreement economically represents an equity issuance cost paid upfront and as such were recorded as general and administrative expenses with an equivalent offset in capital reserves (€664 thousand). As of June 30, 2022, there have been no sales of Class A shares under the Share Purchase Agreement.

Share-based Payments

Share-based Payments	6 Months Ended
	Jun. 30, 2022
Share-based Payments
Share-based Payments	17. Overview Lilium offers several share-based plans as summarized in the table below. All plans are equity-settled, except for new success fees and Joint Stock Option Plan (“JSOP”; including bonus) which are treated as cash-settled. There are no major changes to the plans compared to what was described in the financial statements for 2021 except for the fact that the attrition rate has been modified to reflect a higher expected attrition than assumed before. The table below summarizes the expense/(income) recorded for share-based payments in the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 General population and executives – standard ESOP (equity-settled) 5,225 17,925 General population – RSU 1,728 — Executives – ESOP modified 1,705 — Executives – RSU 1,676 — Executives – Performance-based stock options (919) — Executives – Time-based stock options 3,463 — Executives – Success fees (cash-settled) 2,141 — Executives – Success fee (equity-settled) — 1,506 JSOP incl. bonus (cash-settled) (3,411) — Total expense 11,608 19,431 ​ Standard ESOP The grant date fair value of the equity-settled options was estimated for those participants who received options under the ESOP or who signed the revised agreement which resulted in a capital reserve of €105,867 thousand in total as of June 30, 2022 (December 31, 2021: €100,684 thousand). The expense recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payments 5,225 17,925 Expense arising from cash-settled share-based payments — — ​ The weighted average fair value of options granted during the period was €17,483 thousand (2021: €15,430 thousand). The exercise price for all options is €1. Movements during the period The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the six-months periods ended June 30, 2022 and 2021 (in Lilium N.V. shares): Equity-settled options: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 19,573,307 ​ € 0.00 17,204,854 ​ € 0.00 Granted during the period 5,714 ​ € 0.00 1,279,936 ​ € 0.00 Forfeited during the period (442,835) ​ € 0.00 (285,700) ​ € 0.00 Exercised during the period (8,253,725) ​ € 0.00 — ​ — Transferred to cash-settled (22,856) ​ € 0.00 — ​ — Transferred from cash-settled — ​ — 908,526 ​ € 0.00 Outstanding at June 30 10,859,605 ​ € 0.00 19,107,616 ​ € 0.00 ​ The exact WAEP for all options is €1 divided by 2,857, which is €0.00035 and rounded to nil. Total options that vested during the period were 1,545,389 options (2021: 2,437,021 options). The weighted average share price for exercised options has been €3.77. General population - Restricted Stock Units (“RSU”) The expense recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity settled RSU 1,728 — ​ The agreements have now been finalised and granted, and the general terms and conditions have been fixed. Movements during the periods The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, RSU during the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 162,800 ​ € 0.12 — — Assigned during the period 2,782,614 ​ € 0.12 — — Forfeited during the period (9,837) ​ — — — Outstanding at June 30 2,935,577 ​ € 0.12 — — ​ The weighted average remaining contractual life of RSU is 0.4 years. Measurement of fair values The options are equity settled and have an exercise price of nominal €0.12 per share. The exercise price is significantly lower than the share price at grant date. Accordingly, the intrinsic value of the RSU has been used, i.e. the share price at grant date less the exercise price. During the period, the weighted average fair value of options granted or reasonably expected to be granted in the future is €2.32. Executives - Employee Stock Option Program (“ESOP”) modified Some executives have received ESOP comparable with the general ESOP program, but with individual conditions in respect to the vesting scheme and with different exercise prices. The expense recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payments 1,705 — ​ The total fair value of outstanding options granted was measured at €10,771 thousand. Movements during the periods The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, Lilium N.V. share-based share options during the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 1,888,477 ​ € 7.90 — — Granted during the period — ​ — — — Forfeited during the period (86,796) ​ € 8.90 — — Outstanding at June 30 1,801,681 ​ € 7.85 — — ​ Total options in Lilium N.V. shares vested during the period was 159,995 options (prior period 2021: 0 options). As of June 30, 2022, none of the options granted under the ESOP plan had been exercisable and/or eligible to be settled. The weighted average remaining contractual life is 11.9 years. Measurement of fair values No options have been granted in the first six months 2022 under this plan. Hence, no valuation was necessary due to equity settlement. Executives - Restricted Stock Units (“RSU”) The expense recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity settled RSU 1,676 — ​ Movements during the periods The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 1,050,913 ​ € 0.12 — — Assigned during the period 370,434 ​ € 0.12 — — Forfeited during the period (163,200) ​ € 0.12 — — Exercised during the period (49,548) ​ € 0.12 Outstanding at June 30 1,208,599 ​ € 0.12 — — ​ In the table above, assigned rights include granted rights as well as rights explicitly expected to be granted in the future. 99,609 options are exercisable as of June Measurement of fair values Similar to the RSU for the general population the exercise price is significantly below the share price at grant. While a Black-Scholes model was used to determine the RSU fair market value, the outcome of the valuation basically reflects the intrinsic value of the RSU. Accordingly, input parameters other than the share price are not material. For fair value calculations the share price was taken as the closing price at grant date of Lilium N.V. share. The weighted average fair value of options assigned during the period was €2.95. Executives – Performance-based stock options The income recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Income arising from performance-based stock options (919) — ​ Movements during the periods The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) options WAEP options WAEP Outstanding at January 1 ​ 7,036,501 ​ € 8.15 ​ — ​ — Assigned during the period 1,272,059 ​ € 9.42 — — Forfeited during the period (4,711,839) ​ € 8.66 — — Outstanding at June 30 3,596,721 ​ € 7.93 — — ​ No options are exercisable as of June 30, 2022. The weighted average remaining contractual life is 9.5 years. As of June 1, 2022, 4,341 thousand performance stock options granted to a key management person were forfeited and the expense already recognized from prior years (€1,553 thousand) has been released in general and administrative expense. The forfeiture was the result of a change in responsibilities which result in a different remuneration. In total, 1,006 thousand options were newly granted to the key management person, and an expense of €17 thousand has been recognized for the period January 1 – June 30, 2022. The reason for the grant of the new options was partially as ex-gratia benefit for his services rendered in his former role as well as an incentive for his new role. The number of options therefore take into account the 681 thousand options under the former arrangement, for which the service condition was already fulfilled. The remaining 325 thousand options must fulfill the service vesting condition until 2025 and all options remain subject to the previously agreed performance vesting condition. The exercise price is unchanged, for further details of the plan we refer to the financial statements for the fiscal year 2021. Measurement of fair values The following table lists the inputs to the Black-Scholes model used for the fair market value calculation for new performance-based stock options for the period ended June 30, 2022: ​ ​ ​ ​ ​ June 30, 2022 Risk free rate range 0.60 % - 0.81 % Expected dividend yield — Expected exercise term 3.3 years Expected volatility 109.9 % - 111.4 % ​ The expected volatility was based on an evaluation of the historical volatilities of comparable listed peer group companies. It reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. For fair value calculation the share price was taken as the closing price at grant date of Lilium N.V. The weighted average fair value of options granted during the period was €1.12, the exercise prices are within the range €9.39 - €9.55. The ex-gratia grants are included in the new options above, based on market conditions at June 1, 2022. Executives – Time-based stock options The expense recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from time-based stock options 3,463 — ​ Movements during the periods The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 2,951,000 ​ € 7.25 — — Granted during the period 768,817 ​ € 3.62 — — Forfeited during the period — ​ — — — Outstanding at June 30 3,719,817 ​ € 6.50 — — ​ As of June 30, 2022, in total 567,500 stock options are exercisable. The weighted average remaining contractual life is 9.9 years. Measurement of fair values The following table lists the inputs to the Black-Scholes model used for the fair market value calculation for time-based stock options as of the grant date: ​ ​ ​ ​ ​ ​ June 30, 2022 Risk free rate (0.69 )% – 0.21 % ​ Expected dividend yield — ​ Expected exercise term 9.9 years ​ Expected volatility 121.9 % - 124.1 % ​ ​ The expected volatility was based on an evaluation of the historical volatilities of comparable listed peer group companies. It reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. Other common inputs to option pricing models such as discount rate, dividends expected and expected term. For fair value calculation the share price was taken as the closing price at grant date of Lilium N.V. share. The weighted average fair value of options granted during the period was €1.57. The weighted average exercise price of the option is €3.62. Executives – Success fees The expense recognized for participant services received during the six-months periods ended June 30, 2022 and 2021 is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense for success fees cash-settled 2,141 — Expense for success fee equity-settled — 1,506 Total expense 2,141 1,506 ​ As of June 30, 2022, €4,731 thousand are recorded as provisions in the consolidated statement of financial position. Measurement of success fees The success fees were measured as discounted expected cash flows for the success fee arrangements. The total expense of success fees is calculated as a percentage of the amount raised and recognized over the period of grant date and estimated fundraising dates i.e., over the period when the performance condition is expected to be satisfied. The expected fundraising amounts are adjusted to the probability of fundraising, based on management’s best estimate which is 67 % and a weighted average timing of 1.6 years. Discount rates in the range of 0.32 % to 0.81 % have been applied. Executives - Joint Stock Ownership Plan (JSOP) and bonus Expenses/(income) during the six-months periods ended June 30, 2022 and 2021 from the JSOP and the bonus are shown in the following table, the award is fully vested: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense/(income) for JSOP (2,718) — Expense/(income) for bonus (693) — Total expense/(income) (3,411) — ​ The JSOP and the bonus have been revaluated as of June 30, 2022, and due to the decrease in the share price, an income has been recorded. Advisors – Strategic collaboration agreement (Azul Warrants) The Azul up-front warrants have not been exercised by Azul as of June 30, 2022 and December 31, 2021. For the status of the commitment, refer to note 20.

Warrants And Other Financial Li

Warrants And Other Financial Liabilities	6 Months Ended
	Jun. 30, 2022
Warrants and Other Financial Liabilities
Warrants And Other Financial Liabilities	18. Warrants and other financial liabilities are as follows: ​ ​ ​ ​ ​ ​ in € thousand June 30, 2022 December 31, 2021 Other non-current financial liabilities 23 — Other current financial liabilities 36 — Warrants 5,218 21,405 Total 5,277 21,405 ​

Additional Disclosures on Finan

Additional Disclosures on Financial Instruments	6 Months Ended
	Jun. 30, 2022
Additional Disclosures on Financial Instruments
Additional Disclosures on Financial Instruments	19. The following tables disclose the carrying amounts of each class of financial instruments together with its corresponding fair value: Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 In € thousand Category Carrying amount Fair value Financial assets, by class Cash at banks and petty cash AC 103,132 n/a Fixed term deposit AC 119,561 n/a Security deposits AC 5,870 5,783 Derivative financial assets FVTPL 163 163 Other financial assets AC 16 n/a Total financial assets ​ 228,742 Financial liabilities, by class Trade and other payables (non-current) AC 5,032 4,290 Trade and other payables (current) AC 36,524 n/a Warrants FVTPL 5,218 5,218 Other financial liabilities AC 59 n/a Total financial liabilities ​ 46,833 ​ Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 In € thousand Category Carrying amount Fair value Financial assets, by class Cash at banks and petty cash AC 129,856 n/a Money Market Funds FVTPL 99,919 99,919 Fixed term deposit AC 119,664 n/a Security deposits AC 3,821 n/a Total financial assets ​ 353,260 Financial liabilities, by class Trade and other payables (non-current) AC 2,906 n/a Trade and other payables (current) AC 35,335 n/a Warrants FVTPL 21,405 21,405 Total financial liabilities ​ 59,646 ​ The Public Warrants are traded in an active market and are therefore categorized in level 1 of the fair value hierarchy - the Private Warrants have been treated equally. In addition, money market funds are also categorized as level 1 as traded in an active market. The security deposits and the derivative financial assets are categorized in level 2 of the fair value hierarchy. The fair value of the derivative financial asset is determined based on market-based exchange rates discounted for the remaining term. The fair value of the security deposits is determined as expected cash flows discounted using market-based credit risk adjusted interest rate curves that are applicable for the respective counterparty and specific for the residual term of each financial instrument. The fair value of the non-current accruals that are part of the non-current trade and other payables was calculated in the same way; however, as the credit risk of the Group is not observable at the market, these are categorized in level 3 of the fair value hierarchy. Transfers between levels of the fair value hierarchy are deemed to take place at the end of the period.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies.
Commitments and Contingencies	20. The Group has various lease contracts that have not yet commenced as of June 30, 2022. The future lease payments for these non-cancellable lease contracts are €200 thousand within one year, €1,847 thousand between one and five years and Nil thereafter. The Group has commitments under operating contracts. The future payments for the operating contracts are €49,046 thousand within one year, €104,609 thousand between one and five years and €18,558 thousand thereafter. The commitments under operating contracts increased significantly during the period as a result of entering into a large number of supply-chain agreements to support the readiness for serial production. Further, the Group has commitments of €12,673 thousand to acquire items of property, plant & equipment and commitments of €4,440 thousand to acquire items of intangible assets. The Group is required to issue, subject to the execution of definitive agreements, warrants to purchase up to 6,200,000 Class A shares (the “Azul Additional Warrants”), which are expected to vest in three tranches upon achieving certain performance and market conditions (see note 17). As of the date these condensed interim financial statements were approved, no contracts with respect to the acquisition of Lilium Jets or any other collaboration have been executed. On April 18, 2022, a putative class action was filed against Lilium N.V., Daniel Wiegand, Geoffrey Richardson, and Barry Engle for purported violations of United States securities laws. This lawsuit was filed in the U.S. District Court for the Central District of California and is presently captioned as: Maniraj Ashirwad Gnanaraj v. Lilium N.V. et al., 2:22-CV-02564. The Group’s management believes the claims are without merit and intend to vigorously defend this litigation. The lawsuit is currently at a preliminary stage and the Group cannot predict its outcome, so the Group therefore cannot determine the likelihood of loss or estimate a range of possible loss.

Related Party Disclosures

Related Party Disclosures	6 Months Ended
	Jun. 30, 2022
Related Party Disclosures
Related Party Disclosures	21. Transactions with Key Management Key management personnel have been defined as the members of the Board of Directors and Senior Leadership Team of Lilium. The annual remuneration and related compensation costs recognized as expense during the six-months periods ended June 30, 2022 and 2021 is comprised of the following (number of granted options in Lilium N.V. shares): ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Short-term employee benefits 1,640 1,697 Share-based payment remuneration: - Legacy ESOP (2022: 4,175,163 options; 2021: 5,933,989 options) 2,734 7,107 - Modified ESOP for executives (2022: 1,801,681; 2021: Nil) 1,705 — - RSU (2022: 1,208,599; 2021: Nil) 1,676 — - Stock options (2022: 7,316,538; 2021: Nil) 4,220 — - Success fees (1,270) 1,506 Total 10,705 10,310 ​ Short-term benefits include salaries, bonus and other benefits such as medical, death and disability coverage, company car and other usual facilities as applicable. The share-based payment remuneration represents the compensation cost of standard and modified ESOP, RSU, performance-based and time-based equity awards and success fees. Refer to note 17. Success fee remuneration includes the changes of the Joint Stock Ownership Plan (Stichting JSOP) and of the bonus issued to one member of key management personnel, as described in notes 17. (€2,718) thousand are recognized in general and administrative expenses in relation to the JSOP and (€693) thousand in general and administrative expenses in relation to the bonus. The Group paid €57 thousand (period to June 30, 2021: Nil) in selling expenses and Nil (period to June 30, 2021: €19 thousand) in general and administrative expenses during the period under an existing consulting agreement with an entity controlled by a member of key management personnel. During the period, the Group entered into a new consulting contract with an entity controlled by a member of key management personnel for a total value of €193 thousand ($200 thousand). As of June 30, 2022, the Group recognized €61 thousand in Selling expenses in relation to the contract. In the period ended June 30, 2022, the board members of the Lilium N.V. have received a compensation of €172 thousand (period to June 30, 2021: Nil). Transactions with related parties The Group recognized €94 thousand (period to June 30, 2021: €226 thousand) in research and development expenses in the period under an existing Development agreement with Zenlabs Energy, Inc. During the period, the Group was party to a new investment agreement with Zenlabs Energy, Inc, as described in note 13. As a result of the investment agreement Zenlabs changed from an associate of the Group to a joint venture. The Group recognized €368 thousand gain on dilution in share of loss in a joint venture. The Group recognized €1 thousand (period to June 30, 2021: Nil) in research and development expenses and €92 thousand (period to June 30, 2021: Nil) in selling expenses with other related parties in the period. The Group purchased property, plant and equipment of €5 thousand (period to June 30, 2021: Nil) from other related parties in the period. As of June 30, 2022, the Group held €32 thousand in trade and other payables owed to other related parties. Transactions with shareholders Cloud subscription On March 28, 2021, Lilium entered into a non-cancelable purchase obligation for a cloud subscription with a shareholder (which provides advanced data analytics capability), including support services, updates and related professional services, for €42,433 thousand ($50,000 thousand) payables in increasing annual instalments over five years. This shareholder has no significant influence on Lilium. The Group recognized €4,292 thousand (period to June 30, 2021: €1,278 thousand) in General and Administration expenses. As of June 30, 2022, the Group had prepaid services under the subscription of €951 thousand (as of December 31, 2021: €2,927 thousand) for future costs in non-financial assets. As of June 30, 2022, and December 31, 2021, the Group has remaining commitments of €34,659 thousand and €34,015 thousand on the contract, respectively.

Events after the Reporting Peri

Events after the Reporting Period	6 Months Ended
	Jun. 30, 2022
Events after the Reporting Period
Events after the Reporting Period	22. Share Purchase Agreement (“ELOC”) Between July 5, 2022 and September 15, 2022, the Group issued 4,262,000 Class A Shares to Tumim Stone under the Purchase Agreement referred to in note 16 for cash proceeds of €10,576 thousand. The Group recorded the issued Class A shares at fair value net of equity issuance cost (represented by the discount) by increasing subscribed capital of €511 thousand and share premium of €10,065 thousand. Class B share transactions In July 2022, the Company agreed that up to 375,000 Class B shares can be returned without consideration and 375,000 treasury Class A shares will be offered as compensation. In August 2022, 375,000 Class B shares have been returned and accordingly 375,000 treasury Class A shares have been re-issued to the Class B shareholder who is a related party.

Basis of Preparation and Chan_2

Basis of Preparation and Changes to the Groups Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Basis of Preparation and Changes to the Group's Accounting Policies
New standards, interpretations and amendments adopted by the Group	New standards, interpretations and amendments adopted by the Group The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2021, except for the adoption of new standards effective as of January 1, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several amendments apply for the first time in 2022, but do not have an impact on the interim condensed consolidated financial statements of the Group.

Corporate Information (Tables)

Corporate Information (Tables)	6 Months Ended
	Jun. 30, 2022
Corporate Information
Schedule of equity interest owned by the company in subsidiaries	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ equity interest ​ ​ ​ ​ ​ ​ owned in % ​ ​ ​ Country of ​ Date of ​ June 30, ​ June 30, Name ​ Incorporation ​ incorporation ​ 2022 ​ 2021 ​ Lilium N.V. Netherlands ​ March 11, 2021 100.0 % n/a ​ Lilium GmbH Germany ​ February 11, 2015 100.0 % 100.0 % Lilium Schweiz GmbH Switzerland ​ December 8, 2017 100.0 % 100.0 % Lilium Aviation UK Ltd. United Kingdom ​ December 20, 2017 100.0 % 100.0 % Lilium Aviation Inc. United States ​ July 1, 2020 100.0 % 100.0 % Lilium eAircraft GmbH Germany ​ August 17, 2020 100.0 % 100.0 % Stichting JSOP Netherlands ​ September 10, 2021 0.0 % n/a ​ Lilium Aviation Spain SL Spain ​ April 7, 2022*) 100.0 % n/a ​ *) date of purchase of a shell company (company without active business).

Financial Result (Tables)

Financial Result (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Result
Schedule of financial results	Financial result is comprised of the following for the six-months periods ended June 30, 2022 and 2021: ​ ​ ​ ​ ​ In € thousand 2022 2021 Finance income ​ 16,597 ​ 6,810 thereof: fair value changes 16,350 6,757 thereof: reversal of expected credit losses 124 — Finance expenses (931) (13,094) thereof: interest portion of lease payments (230) (214) thereof: fair value changes (67) (9,391) thereof: expected credit losses (87) — thereof: interest on convertible loans — (3,422) Financial result 15,666 (6,284)

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment
Schedule of Property, plant and equipment	​ ​ ​ ​ ​ ​ In € thousand June 30, 2022 December 31, 2021 Right of use assets – buildings, net ​ 11,519 ​ 10,910 Technical machinery, net 10,083 9,069 Office and other equipment 4,178 4,380 Furniture and fixtures, net 3,672 3,555 Technical machinery under construction 1,014 884 Other, net 1,594 1,812 Property, Plant and Equipment, net 32,060 30,610

Investment in a Joint Venture_2

Investment in a Joint Venture / Associate (Tables)	6 Months Ended
	Jun. 30, 2022
Investment in a Joint Venture / Associate
Schedule of valuation of investment in Zenlabs	​ ​ ​ ​ In € thousand Carrying Value January 1, 2022 ​ 15,054 Share of loss in a joint venture/ associate (1,457) June 30, 2022 13,597

Non-Financial Assets (Tables)

Non-Financial Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Non-Financial Assets
Schedule of Non-financial assets	​ ​ ​ ​ ​ ​ In € thousand June 30, 2022 December 31, 2021 Advance payments ​ 6,251 ​ 8,113 Total non-current non-financial assets 6,251 8,113 Value added tax claims 22,611 12,602 Prepaid expenses 6,905 9,924 Miscellaneous other current non-financial assets 2,432 468 Total current non-financial assets 31,948 22,994 Total non-financial assets 38,199 31,107

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Shareholders' Equity
Schedule of amount of common and preferred shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ Supervoting ​ ​ ​ Lilium ​ ​ shares ​ shares ​ ​ ​ GmbH (in units) (Class A) (Class B) Total Total 1 Outstanding as of January 1, 2021 69,031 — 69,031 69,031 Issued as of January 1, 2021 69,103 — 69,103 69,103 Retrospective application of share split 172,945,103 24,413,065 197,358,168 — Retrospective application of share split (treasury shares) (205,632) — (205,632) — Outstanding as of January 1, 2021, as adjusted 172,808,502 24,413,065 197,221,567 69,031 Issued as of January 1, 2021, as adjusted 173,014,206 24,413,065 197,427,271 69,103 Issued shares - convertible loans 20,533,259 — 20,533,259 7,187 Outstanding as of June 30, 2021, as adjusted 193,341,761 24,413,065 197,221,567 76,218 Issued as of June 30, 2021, as adjusted 193,547,465 24,413,065 197,427,271 76,290 ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of January 1, 2022 259,990,224 24,413,065 284,403,289 — Issued as of January 1, 2022 261,244,915 24,413,065 285,657,980 — Issued shares for share-based payments exercised 8,392,206 — 8,392,206 — Warrants exercised 10 — 10 — ELOC commitment shares 262,697 — 262,697 — Outstanding as of June 30, 2022 268,645,137 24,413,065 293,058,202 — Issued as of June 30, 2022 269,899,828 24,413,065 294,312,893 — 1

Share-based Payments (Tables)

Share-based Payments (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of share-based payment arrangement expense	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 General population and executives – standard ESOP (equity-settled) 5,225 17,925 General population – RSU 1,728 — Executives – ESOP modified 1,705 — Executives – RSU 1,676 — Executives – Performance-based stock options (919) — Executives – Time-based stock options 3,463 — Executives – Success fees (cash-settled) 2,141 — Executives – Success fee (equity-settled) — 1,506 JSOP incl. bonus (cash-settled) (3,411) — Total expense 11,608 19,431
General population and executives - standard ESOP
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payments 5,225 17,925 Expense arising from cash-settled share-based payments — —
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 19,573,307 ​ € 0.00 17,204,854 ​ € 0.00 Granted during the period 5,714 ​ € 0.00 1,279,936 ​ € 0.00 Forfeited during the period (442,835) ​ € 0.00 (285,700) ​ € 0.00 Exercised during the period (8,253,725) ​ € 0.00 — ​ — Transferred to cash-settled (22,856) ​ € 0.00 — ​ — Transferred from cash-settled — ​ — 908,526 ​ € 0.00 Outstanding at June 30 10,859,605 ​ € 0.00 19,107,616 ​ € 0.00
General population - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity settled RSU 1,728 —
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 162,800 ​ € 0.12 — — Assigned during the period 2,782,614 ​ € 0.12 — — Forfeited during the period (9,837) ​ — — — Outstanding at June 30 2,935,577 ​ € 0.12 — —
Executives - ESOP modified
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payments 1,705 —
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 1,888,477 ​ € 7.90 — — Granted during the period — ​ — — — Forfeited during the period (86,796) ​ € 8.90 — — Outstanding at June 30 1,801,681 ​ € 7.85 — —
Executives - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity settled RSU 1,676 —
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Number ​ 2022 ​ Number ​ 2021 (in units) of options WAEP of options WAEP Outstanding at January 1 1,050,913 ​ € 0.12 — — Assigned during the period 370,434 ​ € 0.12 — — Forfeited during the period (163,200) ​ € 0.12 — — Exercised during the period (49,548) ​ € 0.12 Outstanding at June 30 1,208,599 ​ € 0.12 — —
Executives - Performance-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense (income) from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Income arising from performance-based stock options (919) —
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) options WAEP options WAEP Outstanding at January 1 ​ 7,036,501 ​ € 8.15 ​ — ​ — Assigned during the period 1,272,059 ​ € 9.42 — — Forfeited during the period (4,711,839) ​ € 8.66 — — Outstanding at June 30 3,596,721 ​ € 7.93 — —
Schedule of inputs used for measurement of fair values	​ ​ ​ ​ ​ June 30, 2022 Risk free rate range 0.60 % - 0.81 % Expected dividend yield — Expected exercise term 3.3 years Expected volatility 109.9 % - 111.4 %
Executives - Time-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from time-based stock options 3,463 —
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 2,951,000 ​ € 7.25 — — Granted during the period 768,817 ​ € 3.62 — — Forfeited during the period — ​ — — — Outstanding at June 30 3,719,817 ​ € 6.50 — —
Schedule of inputs used for measurement of fair values	​ ​ ​ ​ ​ ​ June 30, 2022 Risk free rate (0.69 )% – 0.21 % ​ Expected dividend yield — ​ Expected exercise term 9.9 years ​ Expected volatility 121.9 % - 124.1 % ​
Executives - Success fees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense for success fees cash-settled 2,141 — Expense for success fee equity-settled — 1,506 Total expense 2,141 1,506
Executives - Joint Stock Ownership plan (JSOP) and bonus
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of expense (income) from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense/(income) for JSOP (2,718) — Expense/(income) for bonus (693) — Total expense/(income) (3,411) —

Warrants And Other Financial _2

Warrants And Other Financial Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Warrants and Other Financial Liabilities
Summary of warrants and other financial liabilities	​ ​ ​ ​ ​ ​ in € thousand June 30, 2022 December 31, 2021 Other non-current financial liabilities 23 — Other current financial liabilities 36 — Warrants 5,218 21,405 Total 5,277 21,405

Additional Disclosures on Fin_2

Additional Disclosures on Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Additional Disclosures on Financial Instruments
Summary of financial instruments, analyzed by classes and categories	Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 In € thousand Category Carrying amount Fair value Financial assets, by class Cash at banks and petty cash AC 103,132 n/a Fixed term deposit AC 119,561 n/a Security deposits AC 5,870 5,783 Derivative financial assets FVTPL 163 163 Other financial assets AC 16 n/a Total financial assets ​ 228,742 Financial liabilities, by class Trade and other payables (non-current) AC 5,032 4,290 Trade and other payables (current) AC 36,524 n/a Warrants FVTPL 5,218 5,218 Other financial liabilities AC 59 n/a Total financial liabilities ​ 46,833 ​ Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 In € thousand Category Carrying amount Fair value Financial assets, by class Cash at banks and petty cash AC 129,856 n/a Money Market Funds FVTPL 99,919 99,919 Fixed term deposit AC 119,664 n/a Security deposits AC 3,821 n/a Total financial assets ​ 353,260 Financial liabilities, by class Trade and other payables (non-current) AC 2,906 n/a Trade and other payables (current) AC 35,335 n/a Warrants FVTPL 21,405 21,405 Total financial liabilities ​ 59,646

Related Party Disclosures (Tabl

Related Party Disclosures (Tables)	6 Months Ended
	Jun. 30, 2022
Related Party Disclosures
Schedule of annual remuneration and related compensation costs recognized as expense	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Short-term employee benefits 1,640 1,697 Share-based payment remuneration: - Legacy ESOP (2022: 4,175,163 options; 2021: 5,933,989 options) 2,734 7,107 - Modified ESOP for executives (2022: 1,801,681; 2021: Nil) 1,705 — - RSU (2022: 1,208,599; 2021: Nil) 1,676 — - Stock options (2022: 7,316,538; 2021: Nil) 4,220 — - Success fees (1,270) 1,506 Total 10,705 10,310

Corporate Information (Details)

Corporate Information (Details)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Lilium N.V.
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%
Lilium GmbH
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%	100%
Lilium Schweiz GmbH
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%	100%
Lilium Aviation UK Ltd.
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%	100%
Lilium Aviation Inc.
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%	100%
Lilium eAircraft GmbH
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%	100%
Stichting JSOP
Corporate Information [Line Items]
Proportion of interest in subsidiary	0%
Lilium Aviation Spain SL
Corporate Information [Line Items]
Proportion of interest in subsidiary	100%

Going Concern (Details)

Going Concern (Details) € in Millions	6 Months Ended
	Jun. 30, 2022 EUR (€)
Going Concern
Cash flows from operations including accumulated losses	€ 841

Research and Development Expe_2

Research and Development Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	€ 83,028	€ 58,762
Personnel expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	38,686
Certification and serial production
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	20,047
Contractor and consulting expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	11,549
Testing component and material cost
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	4,594
Amortization and depreciation expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	2,837
Other miscellaneous expenses
Disclosure of attribution of expenses by nature to their function [line items]
Research and development expense	€ 5,315

General and Administrative Ex_2

General and Administrative Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expense	€ 46,987	€ 38,718
Personnel expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expense	16,895
Contractor and consulting expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expense	14,921
IT costs
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expense	7,653
Director and officers liability insurance
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expense	3,358
Other miscellaneous expenses
Disclosure of attribution of expenses by nature to their function [line items]
General and administrative expense	€ 4,160

Selling Expenses (Details)

Selling Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
Selling expense	€ 9,574	€ 6,376
Personnel expenses
Disclosure of attribution of expenses by nature to their function [line items]
Selling expense	7,319
Other miscellaneous expenses
Disclosure of attribution of expenses by nature to their function [line items]
Selling expense	€ 2,255

Financial Result (Details)

Financial Result (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Financial Result
Finance income	€ 16,597	€ 6,810
thereof: fair value changes	16,350	6,757
thereof: reversal of expected credit losses	124
Finance expenses	(931)	(13,094)
thereof: interest portion of lease payments	(230)	(214)
thereof: fair value changes	(67)	(9,391)
thereof: expected credit losses	(87)
thereof: interest on convertible loans		(3,422)
Financial result	€ 15,666	€ (6,284)

Financial Result - Additional I

Financial Result - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finance Income (Cost) [Line Items]
Fair value changes of warrants included in finance income	€ 16,187
Fair value changes of foreign currency exchange contract included in finance income	163
Fair value changes of money market funds included in finance expense	67
Fair value changes of convertible loans included in finance income		€ 6,757
Fair value changes of foreign currency exchange contract included in finance expense	€ 9,376

Income Taxes (Details)

Income Taxes (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Taxes
Income tax (income) expense	€ (478)	€ 199

Property, Plant and Equipment -

Property, Plant and Equipment - Acquired assets (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Property, Plant and Equipment
Right of use assets - buildings, net	€ 11,519		€ 10,910
Technical machinery, net	10,083		9,069
Office and other equipment	4,178		4,380
Furniture and fixtures, net	3,672		3,555
Technical machinery under construction	1,014		884
Other, net	1,594		1,812
Property, Plant and Equipment, net	€ 32,060	€ 30,610	€ 30,610

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional informations (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment
Acquired assets with a cost	€ 4,320	€ 5,700
Net book value of assets disposed	9	0
Net gain on disposal	€ 0	€ 8

Investment in a Joint Venture_3

Investment in a Joint Venture / Associate (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€) shares
Disclosure of associates [line items]
Gain on dilution of interest in equity | €	€ 368
Zenlabs
Disclosure of associates [line items]
Percentage of issuance stock	31.36%
Issuance of stock	273,227
Shares repurchased	273,227
Zenlabs | Series B preferred stock
Disclosure of associates [line items]
Issuance of stock	350,000

Investment in a Joint Venture_4

Investment in a Joint Venture / Associate - Valuation of investment in Zenlabs (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€)
Disclosure of associates [line items]
Beginning Balance	€ 15,054
Ending Balance	13,597
Zenlabs
Disclosure of associates [line items]
Beginning Balance	15,054
Share of loss in a joint venture/ associate	(1,457)
Ending Balance	€ 13,597

Other Financial Assets (Details

Other Financial Assets (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure of financial assets [line items]
Cash received from matured deposits	€ 79,970
Interest expenses	121
Invested in fixed-term deposits	80,000
Money market funds	€ 99,853	€ 99,919
Fixed term deposit
Disclosure of financial assets [line items]
Term of deposits (in months)	3 months
Fixed term deposit	€ 119,561	€ 119,664
Foreign currency exchange contract
Disclosure of financial assets [line items]
Money market funds	€ 163

Non-Financial Assets (Details)

Non-Financial Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of financial assets [line items]
Advance payments	€ 6,251	€ 8,113
Total non-current non-financial assets	6,251	8,113
Value added tax claims	22,611	12,602
Prepaid expenses	6,905	9,924
Miscellaneous other current non-financial assets	2,432	468
Total current non-financial assets	31,948	22,994
Total non-financial assets	38,199	€ 31,107
Germany
Disclosure of financial assets [line items]
Claims for value added taxes increased	€ 10,009

Shareholders' Equity (Details)

Shareholders' Equity (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Before reorganization
Disclosure of classes of share capital [line items]
Number of shares outstanding, beginning balance		69,031
Number of shares issued, beginning balance		69,103
Outstanding as adjusted, beginning balance		69,031
Issued as adjusted		76,290		69,103
Issued shares - convertible loans		7,187
Outstanding as adjusted, ending balance		76,218
After Reorganization
Disclosure of classes of share capital [line items]
Number of shares outstanding, beginning balance	284,403,289	69,031
Number of shares issued, beginning balance	285,657,980	69,103
Retrospective application of share split			197,358,168
Issued shares for share-based payments exercised	8,392,206
Warrants exercised	10
ELOC commitment shares	262,697
Outstanding as adjusted, beginning balance		197,221,567
Issued as adjusted		197,427,271		197,427,271
Issued shares - convertible loans		20,533,259
Outstanding as adjusted, ending balance		197,221,567
Number of shares outstanding, ending balance	293,058,202
Number of shares issued, ending balance	294,312,893
Treasury shares | After Reorganization
Disclosure of classes of share capital [line items]
Retrospective application of share split			(205,632)
Class A shares
Disclosure of classes of share capital [line items]
Number of shares outstanding, beginning balance	259,990,224	69,031
Number of shares issued, beginning balance	261,244,915	69,103
Retrospective application of share split			172,945,103
Issued shares for share-based payments exercised	8,392,206
Warrants exercised	10
ELOC commitment shares	262,697
Outstanding as adjusted, beginning balance		172,808,502
Issued as adjusted		193,547,465		173,014,206
Issued shares - convertible loans		20,533,259
Outstanding as adjusted, ending balance		193,341,761
Number of shares outstanding, ending balance	268,645,137
Number of shares issued, ending balance	269,899,828
Class A shares | Treasury shares
Disclosure of classes of share capital [line items]
Retrospective application of share split			(205,632)
Class B shares
Disclosure of classes of share capital [line items]
Number of shares outstanding, beginning balance	24,413,065
Number of shares issued, beginning balance	24,413,065
Retrospective application of share split			24,413,065
Outstanding as adjusted, beginning balance		24,413,065
Issued as adjusted		24,413,065		24,413,065
Outstanding as adjusted, ending balance		24,413,065
Number of shares outstanding, ending balance	24,413,065
Number of shares issued, ending balance	24,413,065

Shareholders' Equity - Addition

Shareholders' Equity - Additional information (Details) € / shares in Units, $ in Millions			6 Months Ended
	Jun. 03, 2022 USD ($) shares	Sep. 14, 2021 EUR (€) € / shares shares	Jun. 30, 2022 EUR (€) shares	Jun. 30, 2022 USD ($) shares	Sep. 15, 2022 shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 shares
Disclosure of classes of share capital [line items]
Share split		0.0004
Number of shares transferred to Class B shares | shares		8,545
Share capital			€ 41,177,000			€ 40,138,000
Increase in subscribed capital						29,481,000
Decrease in share premium						(29,456,000)
Decrease in treasury shares						25,000
Shares issued due to execution of vested share based payments | shares			8,392,206	8,392,206
Subscribed capital			€ 1,007,000
Other capital reserves			252,940,000			240,430,000
Share premium			€ 779,347,000			€ 779,141,000
Number of warrants exercised | shares			10	10
Number of shares issued | shares			10	10
Subscribed capital paid			€ 1.20
Capital reserve			103.33
Share based payment liabilities to other capital reserves			€ 5.45
Equity line of credit shares issued compensation for share purchased | shares			262,697	262,697
Equity line of credit payment to subscribed capital			€ 32,000
Remaining fair value of shares expensed to other capital reserves			€ 664,000
Class A shares
Disclosure of classes of share capital [line items]
Number of shares issued | shares		261,244,915	269,899,828		4,262,000	261,244,915	69,103
Nominal value per share | € / shares		€ 0.12
Share capital		€ 31,300,000
Number of shares outstanding | shares			268,645,137			259,990,224	69,031
Number of commitment shares | shares	262,697
Maximum amount committed to purchase subject to certain limitations | $	$ 75
Maximum obligated to purchase of shares commitment | $	$ 75
Total commitment issued of Tumim stone | $				$ 75
Percentage of shares outstanding beneficially owning			4.99%	4.99%
Percentage of ownership shares outstanding beneficially			9.99%	9.99%
Class B shares
Disclosure of classes of share capital [line items]
Number of shares issued | shares		24,413,065	24,413,065			24,413,065
Nominal value per share | € / shares		€ 0.36
Share capital		€ 8,800,000
Number of shares outstanding | shares		24,413,065	24,413,065			24,413,065
Share premium
Disclosure of classes of share capital [line items]
Share premium			€ 206,000
Other capital reserves
Disclosure of classes of share capital [line items]
Other capital reserves			€ 990,000

Share-based Payments - Other pl

Share-based Payments - Other plans (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	€ 11,608	€ 19,431
General population and executives - standard ESOP
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	5,225	17,925
General population - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	1,728
Executives - ESOP modified
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	1,705
Executives - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	1,676
Executives - Performance-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	(919)
Executives - Time-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	3,463
Executives - Success fees (cash-settled)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	2,141
Executives - Success fee (equity-settled)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense		€ 1,506
Executives - Joint Stock Ownership plan (JSOP) and bonus
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense	€ (3,411)

Share-based Payments - Expense

Share-based Payments - Expense recognized for participant services (Details)	6 Months Ended
	Jun. 30, 2022 EUR (€) Y Options € / shares item shares	Jun. 30, 2021 EUR (€) € / shares Options shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from share-based payments | €	€ 11,608,000	€ 19,431,000
Number of options
Outstanding at December 31 | €	4,175,163	5,933,989
Maximum
Measurement of fair values
Expected volatility (%)	111.40%
General population and executives - standard ESOP
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €	€ 5,225,000	€ 17,925,000
Expense arising from share-based payments | €	€ 5,225,000	€ 17,925,000
WAEP
Outstanding at December 31	€ 3.77
General population and executives - standard ESOP | Equity-settled options
Number of options
Outstanding at January 1 | Options	19,573,307	17,204,854
Granted during the year | Options	5,714	1,279,936
Forfeited during the year | Options	(442,835)	(285,700)
Exercised during the period | Options	(8,253,725)
Transferred to cash-settled | shares	(22,856)
Transferred from cash-settled | shares		908,526
Outstanding at December 31 | Options	10,859,605	19,107,616
WAEP
Outstanding at January 1	€ 0	€ 0
Granted during the year	0	0
Forfeited during the year	0	€ 0
Exercised during the period	€ 0
Transferred to cash-settled	0
Transferred from cash-settled		0
Outstanding at December 31	€ 0	€ 0
General population - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €	€ 1,728,000
Expense arising from share-based payments | €	€ 1,728,000
Number of options
Outstanding at January 1 | Options	162,800
Granted during the year	2.32
Assigned during the year | shares	2,782,614
Forfeited during the year | Options	(9,837)
Outstanding at December 31 | Options	2,935,577
WAEP
Outstanding at January 1	€ 0.12
Assigned during the year	0.12
Outstanding at December 31	€ 0.12
Executives - ESOP modified
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €	€ 1,705,000
Expense arising from share-based payments | €	€ 1,705,000
Number of options
Outstanding at January 1 | Options	1,888,477
Granted during the year | Options	0
Forfeited during the year | Options	(86,796)
Outstanding at December 31 | Options	1,801,681
WAEP
Outstanding at January 1	€ 7.90
Forfeited during the year	8.90
Outstanding at December 31	€ 7.85
Executives - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €	€ 1,676,000
Expense arising from share-based payments | €	€ 1,676,000
Number of options
Outstanding at January 1 | Options	1,050,913
Assigned during the year | shares	370,434
Forfeited during the year | Options	(163,200)
Exercised during the period | Options	(49,548)
Outstanding at December 31 | Options	1,208,599
WAEP
Outstanding at January 1	€ 0.12
Assigned during the year	0.12
Forfeited during the year	€ 0.12
Exercised during the period	0.12
Outstanding at December 31	€ 0.12
Executives - Performance-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €	€ (919,000)
Expense arising from share-based payments | €	€ (919,000)
Number of options
Outstanding at January 1 | Options	7,036,501
Assigned during the year | shares	1,272,059
Forfeited during the year | Options	(4,711,839)
Outstanding at December 31 | Options	3,596,721
WAEP
Outstanding at January 1	€ 8.15
Assigned during the year	9.42
Forfeited during the year	€ 8.66
Outstanding at December 31	€ 7.93
Measurement of fair values
Expected exercise term | item	3.3
Executives - Performance-based stock options | Minimum
Measurement of fair values
Expected volatility (%)	109.90%
Risk free rate	0.60%
Executives - Performance-based stock options | Maximum
Measurement of fair values
Risk free rate	0.81%
Executives - Time-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from share-based payments | €	€ 3,463,000
Number of options
Outstanding at January 1 | Options	2,951,000
Granted during the year | Options	768,817
Outstanding at December 31 | Options	3,719,817
WAEP
Outstanding at January 1	€ 7.25
Granted during the year	3.62
Outstanding at December 31	€ 6.50
Measurement of fair values
Expected exercise term | item	9.9
Executives - Time-based stock options | Minimum
Measurement of fair values
Expected volatility (%)	121.90%
Risk free rate	(0.69%)
Executives - Time-based stock options | Maximum
Measurement of fair values
Expected volatility (%)	124.10%
Risk free rate	0.21%
Executives - Success fees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €		€ 1,506,000
Expense arising from cash-settled share-based payments | €	€ 2,141,000
Expense arising from share-based payments | €	€ 2,141,000	€ 1,506,000
Measurement of fair values
Expected volatility (%)	67%
Expected exercise term | Y	1.6
Executives - Joint Stock Ownership plan (JSOP) and bonus
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from share-based payments | €	€ (3,411,000)
Executives - Joint Stock Ownership plan (JSOP)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from share-based payments | €	(2,718,000)
Executives - shadow bonus
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from share-based payments | €	€ (693,000)

Share-based Payments - Measurem

Share-based Payments - Measurement of fair values (Details) € in Thousands		6 Months Ended		12 Months Ended
	Jun. 01, 2022 EUR (€)	Jun. 30, 2022 EUR (€) Options € / shares Y item shares	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 EUR (€) Options € / shares shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Key managements remuneration | €		€ 10,705	€ 10,310
Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)		111.40%
General population and executives - standard ESOP
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of share-based awards | €		€ 105,867		€ 100,684
Total fair value of options granted | €		€ 17,483		€ 15,430
Exercise price		€ 1
Weighted average exercise price for all option		€ 3.77
Number of options vested | shares		1,545,389		2,437,021
General population - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price		€ 0.12
Weighted average exercise price for all option		€ 0.12		€ 0.12
Weighted average remaining contractual life (in years)		4 months 24 days
Number of options granted		2.32
Executives - ESOP modified
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total fair value of options granted | €		€ 10,771
Weighted average exercise price for all option		€ 7.85		€ 7.90
Weighted average remaining contractual life (in years)		11 years 10 months 24 days
Number of options granted | Options		0
Number of options exercisable | Options		159,995		0
Executives - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price for all option		€ 0.12		€ 0.12
Weighted average remaining contractual life (in years)		1 year 8 months 12 days
Number of options exercisable | Options		99,609
Weighted average fair value of options granted		2.95
Executives - Performance-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price for all option		€ 7.93		8.15
Weighted average remaining contractual life (in years)		9 years 6 months
Number of options exercisable | Options		0
Key managements remuneration | €	€ 4,341
Expenses recognized | €		€ 17
Options under the former arrangement | €		681
Remaining share options value in share based payment for service vesting arrangement | €		€ 325
Weighted average fair value of options granted		1.12
Weighted average timing period (in years) | item		3.3
Executives - Performance-based stock options | General and Administrative Expenses
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expenses recognized | €	€ 1,553
Executives - Performance-based stock options | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value of options granted		9.39
Expected volatility (%)		109.90%
Executives - Performance-based stock options | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value of options granted		9.55
Executives - Restricted Stock Units Option
Disclosure of terms and conditions of share-based payment arrangement [line items]
Key managements remuneration | €		€ 1,006
Executives - Time-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price for all option		€ 6.50		€ 7.25
Weighted average remaining contractual life (in years)		9 years 10 months 24 days
Number of options granted | Options		768,817
Number of options exercisable | Options		567,500
Weighted average exercise price of the option		€ 3.62
Weighted average fair value of options granted		1.57
Weighted average timing period (in years) | item		9.9
Executives - Time-based stock options | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)		121.90%
Executives - Time-based stock options | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)		124.10%
Executives - Success fees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Provision made for payments | €		€ 4,731
Expected volatility (%)		67%
Weighted average timing period (in years) | Y		1.6
Executives - Success fees | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Discount rate (in percent)		0.32%
Executives - Success fees | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Discount rate (in percent)		0.81%

Warrants and Other Financial _3

Warrants and Other Financial Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Warrants and Other Financial Liabilities
Other non-current financial liabilities	€ 23
Other current financial liabilities	36
Warrants	5,218	€ 21,405
Total	€ 5,277	€ 21,405

Additional Disclosures on Fin_3

Additional Disclosures on Financial Instruments - Financial assets, by class (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of financial assets [line items]
Carrying amount	€ 228,742	€ 353,260
Financial assets measured at amortized cost | Cash at banks and petty cash
Disclosure of financial assets [line items]
Carrying amount	103,132	129,856
Financial assets measured at amortized cost | Fixed term deposit
Disclosure of financial assets [line items]
Carrying amount	119,561	119,664
Financial assets measured at amortized cost | Security deposits
Disclosure of financial assets [line items]
Carrying amount	5,870	3,821
Fair value	5,783
Financial assets measured at amortized cost | Other financial assets
Disclosure of financial assets [line items]
Carrying amount	16
FVTPL | Money Market Funds
Disclosure of financial assets [line items]
Carrying amount		99,919
Fair value		€ 99,919
FVTPL | Derivative financial assets
Disclosure of financial assets [line items]
Carrying amount	163
Fair value	€ 163

Additional Disclosures on Fin_4

Additional Disclosures on Financial Instruments - Financial liabilities, by class (Details) - EUR (€) € in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure of financial liabilities [line items]
Carrying amount	€ 46,833	€ 59,646
Financial liabilities measured at amortized cost | Trade and other payables (non-current)
Disclosure of financial liabilities [line items]
Carrying amount	5,032	2,906
Fair value	4,290
Financial liabilities measured at amortized cost | Trade and other payables (current)
Disclosure of financial liabilities [line items]
Carrying amount	36,524	35,335
Financial liabilities measured at amortized cost | Other financial liabilities
Disclosure of financial liabilities [line items]
Carrying amount	59
FVTPL | Warrants
Disclosure of financial liabilities [line items]
Carrying amount	5,218	21,405
Fair value	€ 5,218	€ 21,405

Commitments and Contingencies (

Commitments and Contingencies (Details) € in Thousands	6 Months Ended
	Jun. 30, 2022 EUR (€) tranche shares
Disclosure of maturity analysis of operating lease payments [line items]
Warrants to purchase shares of common stock | shares	6,200,000
Number of tranches upon achieving certain performance and market conditions | tranche	3
Property, plant and equipment
Disclosure of maturity analysis of operating lease payments [line items]
Commitments to acquire assets	€ 12,673
Intangible assets
Disclosure of maturity analysis of operating lease payments [line items]
Commitments to acquire assets	4,440
Within one year
Disclosure of maturity analysis of operating lease payments [line items]
Future lease payments for non-cancellable lease contracts not yet commenced	200
Future payments for operating contracts	49,046
Between one and five years
Disclosure of maturity analysis of operating lease payments [line items]
Future lease payments for non-cancellable lease contracts not yet commenced	1,847
Future payments for operating contracts	104,609
Thereafter
Disclosure of maturity analysis of operating lease payments [line items]
Future lease payments for non-cancellable lease contracts not yet commenced	0
Future payments for operating contracts	€ 18,558

Related Party Disclosures - Ann

Related Party Disclosures - Annual remuneration and related compensation costs recognized as expense (Details)	6 Months Ended
	Jun. 30, 2022 EUR (€) shares	Jun. 30, 2021 EUR (€) shares
Related Party Disclosures
Short-term employee benefits	€ 1,640,000	€ 1,697,000
Share-based payment remuneration: - Legacy ESOP (2022: 4,175,163 options; 2021: 5,933,989 options)	2,734,000	7,107,000
Share-based payment remuneration: - Modified ESOP for executives (2022: 1,801,681; 2021: Nil)	1,705,000
Share-based payment remuneration: - RSU (2022: 1,208,599; 2021: Nil)	1,676,000
Share-based payment remuneration: - Stock options (2022: 7,316,538; 2021: Nil)	4,220,000
Share-based payment remuneration: - Success fees	(1,270,000)	1,506,000
Total	€ 10,705,000	€ 10,310,000
Sharebased payment,stock option	4,175,163	5,933,989
Modified ESOP for executives in shares | shares	1,801,681	0
RSU (in Shares) | shares	1,208,599	0
Stock options in shares | shares	7,316,538	0

Related Party Disclosures - Add

Related Party Disclosures - Additional Information (Details) € in Thousands, $ in Thousands		6 Months Ended
	Mar. 28, 2021 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 EUR (€)	Dec. 31, 2021 EUR (€)	Mar. 28, 2021 EUR (€)
Disclosure of transactions between related parties [line items]
Success fee remuneration		€ (1,270)		€ 1,506
Compensation		10,705		10,310
Recognized related to the contract		32
Property, plant and equipment purchased from a related party		5		0
Expenses incurred in connection with related party		92
Term for Installment Payments | $	$ 50,000
Board members
Disclosure of transactions between related parties [line items]
Compensation		172		0
Joint Stock Ownership Plan
Disclosure of transactions between related parties [line items]
Expenses incurred in connection with related party		368
Cloud subscription
Disclosure of transactions between related parties [line items]
Recognized related to the contract		34,659			€ 34,015
Cloud subscription | Shareholders
Disclosure of transactions between related parties [line items]
Purchase obligation						€ 42,433
General and Administrative Expenses
Disclosure of transactions between related parties [line items]
Consulting services to entity controlled by member of Key Management Personnel		0		19
General and Administrative Expenses | Joint Stock Ownership Plan
Disclosure of transactions between related parties [line items]
Success fee remuneration		2,718
General and Administrative Expenses | Shadow bonus
Disclosure of transactions between related parties [line items]
Success fee remuneration		693
General and Administrative Expenses | Cloud subscription
Disclosure of transactions between related parties [line items]
Expenses incurred in connection with related party		4,292		1,278
Prepaid expenses for future costs in non-financial assets		951			€ 2,927
Selling Expenses
Disclosure of transactions between related parties [line items]
Consulting services to entity controlled by member of Key Management Personnel		57		0
Recognized related to the contract		61
Expenses incurred in connection with related party				0
Consulting Contract
Disclosure of transactions between related parties [line items]
Consulting services to entity controlled by member of Key Management Personnel		193	$ 200
Research And Development Expenses
Disclosure of transactions between related parties [line items]
Expenses incurred in connection with related party		1		0
Research And Development Expenses | Transactions with related parties
Disclosure of transactions between related parties [line items]
Expenses incurred in connection with related party		€ 94		€ 226

Events after the Reporting Pe_2

Events after the Reporting Period (Details) - EUR (€)	2 Months Ended
	Sep. 15, 2022	Aug. 31, 2022	Jul. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 14, 2021	Dec. 31, 2020
Disclosure of non-adjusting events after reporting period [line items]
Treasury Shares				€ 151,000	€ 151,000
Class B shares
Disclosure of non-adjusting events after reporting period [line items]
Shares issued				24,413,065	24,413,065	24,413,065
Share returned without Consideration		375,000	375,000
Class A shares
Disclosure of non-adjusting events after reporting period [line items]
Shares issued	4,262,000			269,899,828	261,244,915	261,244,915	69,103
Proceeds from the Reorganization	€ 10,576,000
Treasury Shares		€ 375,000	€ 375,000
Class A shares | Subscribed capital
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from the Reorganization	511,000
Class A shares | Share premium
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from the Reorganization	€ 10,065,000